Ceregene Has Initiated A New Phase 1/2 Trial Of CERE-120 For Parkinson’s Disease
By admin
Ceregene, Inc., a biopharmaceutical company, announced that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson’s disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up. The new study was initiated in the fourth quarter of 2009 and is proceeding as planned… (Source: Health News from Medical News Today)
MedWorm Message: Get the very latest Swine Flu news via the MedWorm – updated hourly from thousands of authoritative health and news sources.
URL: http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&t=Swine+Flu&f=infectiousdiseases&r=Any&o=d
Related Post
- Zinc Finger Protein Designed to Target 2-Long Terminal Repeat Junctions Interferes with Human Immunodeficiency Virus Integration - May 13th, 2012
- A Shield Against Chemotherapy - May 13th, 2012
- Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome - May 13th, 2012
- A paradigm shift in the delivery of services for diagnosis of inherited retinal disease - May 13th, 2012
- Interferon-alpha enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma - May 13th, 2012
- HIV Gene Therapy Safe Over Time (CME/CE) - May 6th, 2012
- Nanovector delivery of siRNA for cancer therapy - May 6th, 2012
- Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model - May 6th, 2012
- Interferon-? lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-? gene transfer to human tumor cells - May 6th, 2012
- MicroRNA silencing improves the tumor specificity of adenoviral transgene expression - May 6th, 2012
- Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC - May 6th, 2012
- Gene Hunt Is On for Mental Disabilities in Children - May 6th, 2012
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning - May 6th, 2012
- MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy - May 6th, 2012
- Critical Variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency - May 6th, 2012
- Study: Gene Therapy for HIV Safe, But Effectiveness Still Unclear - May 6th, 2012
- April 2012 Advances: Additional Resources - May 6th, 2012
- Scientists find 10 subsets of breast cancer - April 29th, 2012
- Synthetic Biologics Appoints Michael Kaleko, M.D., Ph.D., as Scientific Director - April 29th, 2012
- Genetic test could pave the way for breast cancer 'magic bullets' - April 29th, 2012
- Researchers discover two new genetic loci for obesity - April 29th, 2012
- 'Genetic Fix' From AVI Biopharma Builds Key Muscle Function Protein - April 29th, 2012
- Genetic testing for drug intolerance - April 29th, 2012
- Brooklyn godsend for teen with rare genetic disorder - April 29th, 2012
- Genetic Technologies' Subsidiary Update - April 29th, 2012
- Will we ever correct diseases before birth? | Not Exactly Rocket Science - April 29th, 2012
- Amsterdam Molecular Therapeutics Receives Further Opinion on Glybera® Marketing Authorisation Application - April 29th, 2012
- Gene therapy helps woman to write - April 29th, 2012
- Greenwich gala celebrates cancer therapy breakthrough - April 29th, 2012
- Gene therapy group looks to new frontiers in fight against cancer - April 29th, 2012
- Video: Gene therapy reverses Parkinson's symptoms: study - April 29th, 2012
- New York Mesothelioma Lawyer Applauds Advances in Gene Therapy Cited in New Book - April 29th, 2012
- Gene Therapy Restores Sight to Three Patients - April 29th, 2012
- Global Gene Therapy Industry - April 29th, 2012
- Research and Markets: Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders - April 29th, 2012
- Epirubicin potentiates recombinant adeno?associated virus type 2/5–mediated TRAIL expression in fibroblast?like synoviocytes and augments the antiarthritic effects of rAAV2/5?TRAIL - April 29th, 2012
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results - April 29th, 2012
- Prospects for gene transfer for clinical heart failure - April 29th, 2012
- Gene therapy for ventricular tachyarrhythmias - April 29th, 2012
- Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection - April 29th, 2012
Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research



April 30th, 2010